| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
Form 4: Martini Jeffrey S, Chief Scientific Officer
Received 6,250 shares by exercise or conversion ($51.5K) · Sold 6,250 shares ($1.04M) · Received 6,250 shares by exercise or conversion ($61.2K) · 1 more |
| 10 Nov 2026 | 144 |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027 |
| 28 Oct 2026 | SCHEDULE 13G/A |
| 28 Oct 2026 |
8-K: Other Events
Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set |
| 23 Oct 2026 |
Form 4: Goin Kathleen, Chief Operating Officer
Received 4,313 shares by exercise or conversion ($35K) · Sold 4,313 shares ($537K) |
| 21 Oct 2026 | 144 |
| 14 Oct 2026 |
Form 4: Jenkins George M, Director
Sold 13,152 shares ($1.76M) · Sold 7,174 shares ($935K) · Sold 7,174 shares ($886K) |
| 13 Oct 2026 | 144 |
| 18 Sep 2026 |
Form 4: Goin Kathleen, Chief Operating Officer
Received 4,302 shares by exercise or conversion ($34.9K) · Sold 4,302 shares ($655K) |
| 16 Sep 2026 | 144 |
| 15 Sep 2026 |
Form 4: Jenkins George M, Director
Sold 12,371 shares ($1.87M) · Sold 13,352 shares ($2.03M) · Sold 1,777 shares ($267K) |
| 11 Sep 2026 | 144 |
| 04 Sep 2026 |
Form 4: Kiritsy Christopher P, Director
Received 313 shares by exercise or conversion ($39.8K) · Sold 313 shares ($49.1K) |
| 02 Sep 2026 | 144 |
| 20 Aug 2026 |
Form 4: Goin Kathleen, Chief Operating Officer
Received 4,302 shares by exercise or conversion ($34.9K) · Sold 4,302 shares ($655K) |
| 19 Aug 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
Loading...